Table 1.

Univariate and multivariate Cox analyses on survival models in patients with resecable CRLM neoadjuvant bevacizumab plus FOLFIRI.

		PFS					CSS
		Univariate analysis		Multivariate analysis			Univariate analysis		Multivariate analysis
Variable	N	HR (95% CI)	p value	HR (95% CI)	p value	N	HR (95% CI)	p value	HR (95% CI)	p value
Age (years; ≤ median/ > median)	19/14	1.476 (0.686–3.273)	0.309			19/14	1.057 (0.417–2.677)	0.903
Gender (male/female)	20/13	2.821 (1.345–6.541)	0.007			20/13	4.038 (1.503–9.870)	0.005	12.404 (1.468–104.790)	0.021
KRAS mutational status (Wt/Mut)	16/10	0.6216 (0.220–1.560)	0.285			16/10	0.401 (0.090–1.027)	0.055
Liver metastasis (metachronus/synchronus)	11/22	0.611 (0.275–1.350)	0.223			11/22	0.418 (0.175–1.167)	0.101
Number of metastatic lesions (≤ 3/ > 3)	20/13	0.550 (0.201–1.169)	0.107			20/13	0.543 (0.189–1.338)	0.168
Size of metastatic lesions (cm) (≤ 3/ > 3)	14/19	0.413 (0.169–0.888)	0.025			14/19	0.079 (0.062–0.480)	0.001
Metastases surgical outcome (R0/R1–R2)	28/5	0.569 (0.098–2.226)	0.341			28/5	0.305 (0.028–0.654)	0.013	3.507 (0.930–13.217)	0.065
CXCR4 expression (negative-low/high)	10/21	0.232 (0.091–0.529)	0.001	3.405 (1.701–17.338)	0.004	10/21	0.079 (0.062–0.480)	0.0008
CXCR7 expression (negative-low/high)	16/14	0.479 (0.179–1.002)	0.050			16/14	0.444 (0.162–1.144)	0.092
PD-L1 mRNA T/H ratio (low < 1/high > 1)	10/18	2.024 (0.882–7.309)	0.084	0.315 (0.142–0.869)	0.026	10/18	1.963 (0.728–6.816)	0.160